Exchange: NASDAQ·Updated 09:37 AM EDT
DRIO logo

DRIODarioHealth Corp

$6.09
$0.0617
(1.00%)
Today
EarningsAug 14
Mkt Cap$44.97M
Vol529.00
News
all
press releases
DarioHealth (DRIO) Upgraded to Buy: Here's Why
DarioHealth (DRIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital...
PR Newswire
News Placeholder
Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching...
PR Newswire
News Placeholder
DarioHealth Q1 Earnings Call Highlights
DarioHealth Q1 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
DarioHealth Reports Q1 2026 Results: Full Earnings Call Transcript
DarioHealth Reports Q1 2026 Results: Full Earnings Call Transcript...
Yahoo! Finance: News
News Placeholder
DarioHealth Corp. (DRIO) Reports Q1 Loss, Beats Revenue Estimates
DarioHealth (DRIO) delivered earnings and revenue surprises of -14.09% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +25.00% and -30.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Encompass Health to Expand Idaho Presence With New 50-Bed Facility
EHC plans a new 50-bed inpatient rehab hospital in Post Falls, expanding its footprint in an underserved market with an expected 2028 opening.
Zacks
News Placeholder
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of +41.18% and +2.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.